Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REPEAT: Repeated Exposure to Eltrombopag in Chronic ITP
2006-002943-10Phase 2Completed
- Sponsor
- GSK
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eltrombopag in immune thrombocytopenia (ITP), sponsored by GSK. Primary endpoint: Consistency (durability of platelet response). Started Feb 2007; status: completed.
02
Drugs
eltrombopag
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2006-002943-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002943-10.